SGLT2抑制劑之”心”發現

SGLT2 inhibitors : A New Era in the Treatment of Heart Failure

徐雅玫(Ya-Mei, Hsu)

《彰化護理》 30卷1期 (2023/03) Pp. 20-25

https://doi.org/10.6647/CN.202303_30(1).0005

摘要

隨著人口老化，臺灣心衰竭的病人逐年增加。心衰竭藥物治療變更為四大類，指引導向藥物治療在心衰竭合併射出分率減少族群新增加了SGLT2抑制劑。SGLT2抑制劑已被證明對多種疾病具有心臟和腎臟保護作用，包括第二型糖尿病、慢性腎病和心衰竭。在心衰竭病人族群，SGLT2抑制劑的臨床益處首先在心衰竭合併射出分率減少的病人中得到證實，現在被強烈推薦作為糖尿病合併心衰竭的首選藥物。

關鍵字

第2型鈉－葡萄糖共同轉運蛋白抑制劑 ； 心衰竭 ； dapagliflozin ； empagliflozin

並列摘要

Heart failure is a growing epidemic, especially in Taiwan because of the aging population. Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) now includes 4 medication classes that include SGLT2 inhibitors. SGLT2 inhibitors have been shown to have salutary cardioprotective and renoprotective effects in various diseases including type 2 diabetes, chronic kidney disease, and heart failure. In patients with heart failure, the clinical benefits of SGLT2 inhibitors were first established in those with reduced ejection fraction and are now strongly recommended as first-line treatment in patients with diabetes mellitus and heart failure.

並列關鍵字

Sodium glucose cotransporter 2 inhibitors ； SGLT2 inhibitors ； heart failure ； dapagliflozin ； empagliflozin

參考文獻

McMurray, J. J., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., ... & Langkilde, A. M. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995-2008. https://doi.org/ 10.1056/NEJMoa1911303

Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., ... & Zannad, F. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine, 383(15), 1413-1424.https://doi.org/ 10.1056/NEJMoa2022190

Vaduganathan, M., Docherty, K. F., Claggett, B. L.,Jhund, P. S., de Boer, R. A., Hernandez, A. F., ... & Solomon, S. D. (2022). SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. The Lancet, 400(10354), 757-767.https://doi.org/10.1016/S0140-6736(22)01429-5

Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., ... & Inzucchi, S. E.(2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New england journal of medicine, 373(22), 2117-2128.https://doi.org/10.1056/NEJMoa1504720

中華民國心臟衰竭照護學會(2019，11月09日)．心衰竭護理指導手冊。取自 https://www.heartfailure.tw/health_edu/nursing/96